Garuda Therapeutics Stock

garudatx.comHealthcare / BioTech & PharmaFounded: 2021

Garuda Therapeutics offers platform technology that aids in the development of off-the-shelf hematopoietic stem cell (HSC) therapies that treat a range of severe and life-threatening diseases. The goal of the company is to make it easier for patients to access stem-cell therapies by providing consistent, durable, and HLA-compatible treatments for a broad range of diseases. Garuda Therapeutics was founded in the Boston, Massachusetts area in 2021.

Register for Details

For more details on financing and valuation for Garuda Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Garuda Therapeutics.

Register Today

Other companies like Garuda Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$1.33B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$405.17MM

News Highlights

Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital.
Updated on: Oct 4, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.